News & Events

Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels

Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcast NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides

NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported